Drugs / ACT-774312
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03688555 | Oct 2018 → Nov 2020 | nasal cavity polyp | Idorsia Pharmaceuticals Ltd. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACT-774312 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03688555 ↗ |
| Modality | Small molecule | — CHEMBL6068505 ↗ |